Raddþjálfun einstaklinga með parkinsonsveiki: Mat á ... - Skemman

Spielman, J., Borod, J. C. og Ramig, L. O. (2003). The effects of intensive voice treatment on facial
expressiveness in Parkinson disease: Preliminary data. Cognitive and Behavioral Neurology,
16(3), 177-188.
Spielman, J., Mahler, L., Halpern, A., Gilley, P., Klepitskaya, O. og Ramig, L. (2011). Intensive voice
treatment (LSVT ® LOUD) for Parkinson's disease following deep brain stimulation of the
subthalamic nucleus. Journal of Communication Disorders, 44(6), 688-700.
Spielman, J., Ramig, L. O., Mahler, L., Halpern, A. og Gavin, W. J. (2007). Effects of an extended
version of the Lee Silverman Voice Treatment on voice and speech in Parkinson's disease.
American Journal of Speech-Language Pathology, 16(2), 95-107.
Stewart, C., Winfield, L., Hunt, A., Bressman, S. B., Fahn, S., Blitzer, A. o.fl. (1995). Speech
dysfunction in early Parkinson's disease. Movement Disorders, 10(5), 562-565.
Stranding, S., Crossman, A. R., FitzGerald, M. J. T. og Collins, P. (2005). Basal ganglia. Í S. Stranding
(Ritstj.), Gray's anatomy: The anatomical basis of clinical practice (39. útgáfa, bls. 325-334).
New York, USA: Elsevier Churchill Livingstone.
Tan, E. K., Ratnagopal, P., Han, S. Y. og Wong, M. C. (2003). Piribedil and bromocriptine in
Parkinson's disease: A single-blind crossover study. Acta Neurologica Scandinavia, 107(3),
202-206.
Tate, R. L., McDonald, S., Perdices, M., Togher, L., Schultz, R. og Savage, S. (2008). Rating the
methodological quality of single-subject designs and n-of-1 trials: Introducing the Single-Case
Experimental Design (SCED) Scale. Neuropsychological Rehabilitation, 18(4), 385-401.
Tillerson, J. L., Cohen, A. D., Caudle, W. M., Zigmond, M. J., Schallert, T. og Miller, G. W. (2002).
Forced nonuse in unilateral parkinsonian rats exacerbates injury. The Journal of
Neuroscience, 22(15), 6790-6799.
Tillerson, J. L., Cohen, A. D., Philhower, J., Miller, G. W., Zigmond, M. J. og Schallert, T. (2001).
Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine.
The Journal of Neuroscience, 21(12), 4427-4435.
Van Den Eeden, S. K., Tanner, C. M., Bernstein, A. L., Fross, R. D., Leimpeter, A., Bloch, D. A. o.fl.
(2003). Incidence of Parkinson's disease: Variation by age, gender, and race/ethnicity.
American Journal of Epidemiology, 157(11), 1015-1022.
von Campenhausen, S., Bornschein, B., Wick, R., Bötzel, K., Sampaio, C., Poewe, W. o.fl. (2005).
Prevalence and incidence of Parkinson's disease in Europe. European
Neuropsychopharmacology, 15(4), 473-490.
Vučković, M. G., Li, Q., Fisher, B., Nacca, A., Leahy, R. M., Walsh, J. P. o.fl. (2010). Exercise elevates
dopamine D2 receptor in a mouse model of Parkinson's disease: In vivo imaging with
[ 18 F]fallypride. Movement Disorders, 25(16), 2777-2784.
Williams-Gray, C. H., Evans, J. R., Goris, A., Foltynie, T., Ban, M., Robbins, T. W. o.fl. (2009). The
distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN
cohort. Brain, 132(Pt 11), 2958-2969.
Williams-Gray, C. H., Foltynie, T., Brayne, C. E., Robbins, T. W. og Barker, R. A. (2007). Evolution of
cognitive dysfunction in an incident Parkinson's disease cohort. Brain, 130(Pt 7), 1787-1798.
Wise, R. J., Greene, J., Büchel, C. og Scott, S. K. (1999). Brain regions involved in articulation. The
Lancet, 353(9158), 1057-1061.
Yorkston, K. M. (1996). Treatment Efficacy: Dysarthria. Journal of Speech and Hearing Research,
39(5), S46-57.
Yorkston, K. M., Hakel, M., Beukelman, D. R. og Fage, S. (2007). Evidence for effectiveness of
treatment of loudness, rate, or prosody in dysarthria: A systematic review. Journal of Medical
Speech-Language Pathology, 15(2), xi-xxxvi.
Zwirner, P. og Barnes, G. J. (1992). Vocal tract steadiness: A measure of phonatory and upper airway
motor control during phonation in dysarthria. Journal of Speech and Hearing Research, 35(4),
761-768.
73